Phase II trial using imatinib combined with chemotherapy for newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)
Phase 2
Recruiting
- Conditions
- ewly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)
- Registration Number
- JPRN-UMIN000001226
- Lead Sponsor
- Japan Adult Leukemia Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
Not provided
Exclusion Criteria
1) Infectious disease of Grade 4 2) Positive HIVAb or HBsAg 3) Active cancer other than ALL 4) Female patients who are pregnant or breast-feeding 5) Reject by responsible physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method